Dr Hal Landy

Dr Hal Landy has been appointed VP medical affairs and chief medical officer of Enobia Pharma, a privately held biotechnology firm in Montreal. Landy has expertise in enzyme replacement therapies, pediatric disorders and orphan products and joins Enobia as it brings its first compound into the clinic. Prior to Enobia, he was VP clinical development at Repligen Corp, Waltham MA. Landy received his MD from Columbia Univ in 1981 and was an instructor in pediatrics at Harvard Medical School from 1989 to 1996. Enobia develops enzyme replacement therapies and other compou